ROCKET PHARMACEUTICALS, INC.
RCKTReported to SECin USCIK 0001281895Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 21. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Wilson MartinGeneral Counsel | Open-market sell | $256,46475,364 shares | Sep 15, 2026 | Wilson MartinGeneral Counsel | $256,464 | Open-market sell | 75,364 | Sep 15, 2026 |
| Wilson MartinGeneral Counsel | Open-market sell | $2,133631 shares | Aug 20, 2026 | Wilson MartinGeneral Counsel | $2,133 | Open-market sell | 631 | Aug 20, 2026 |
| Shah GauravCEO | Open-market sell | $7,7532,293 shares | Aug 20, 2026 | Shah GauravCEO | $7,753 | Open-market sell | 2,293 | Aug 20, 2026 |
| Shah GauravCEO | Open-market sell | $9,5922,837 shares | Aug 17, 2026 | Shah GauravCEO | $9,592 | Open-market sell | 2,837 | Aug 17, 2026 |
| Wilson MartinGeneral Counsel | Open-market sell | $11,8103,493 shares | Aug 17, 2026 | Wilson MartinGeneral Counsel | $11,810 | Open-market sell | 3,493 | Aug 17, 2026 |
Lobbying
From the quarterly LD-2 filings at the U.S. Senate — a different register, and a different kind of fact.
This is not a trade and it is not scored. A lobbying filing says who lobbied for whom, on which issues, and for how much — it says nothing about the share price and nothing about this company’s insiders. The link between the client names in that register and ROCKET PHARMACEUTICALS, INC. is a reviewed rule of ours: an LD-2 names a client and carries no ticker, no CIK and no LEI.
Lobbying reported per quarter
reported amounts per quarter, latest version of each report
Reported income: what lobbying firms reported receiving from this company's clients, per quarter.
Before 2025, these bars cover only the lobbying relationships that were still active in 2025 or later. Engagements that ended earlier are not included, so those years may be higher than shown.